Last updated: February 2, 2026
Summary of Case Context
Gilead Sciences, Inc. filed patent infringement litigation against Teva Pharmaceuticals USA, Inc., alleging infringement of patents related to Gilead’s HCV (hepatitis C virus) treatments, specifically targeting DAAs (direct-acting antivirals). The case, 1:18-cv-00466, was filed in the District of Delaware on March 1, 2018.
The core dispute centers on Gilead’s patent portfolio covering genotypic variants of HCV protease inhibitors and their methods of use, which Teva purportedly sought to infringe through its generic HCV medications.
Case Overview
| Aspect |
Details |
| Court |
District of Delaware |
| Case Number |
1:18-cv-00466 |
| Filing Date |
March 1, 2018 |
| Parties |
Gilead Sciences, Inc. (Plaintiff) vs. Teva Pharmaceuticals USA, Inc. (Defendant) |
| Jurisdiction |
Federal patent law (35 U.S.C.) |
Core Patents in Dispute
| Patent Number |
Title / Focus |
Grant Date |
Patent Family Focus |
| US Patent 9,043,394 |
Composition of compounds, including SOLD, for HCV |
May 26, 2015 |
Composition of matter; HCV treatment compounds |
| US Patent 9,498,390 |
Methods of treating HCV |
Nov 22, 2016 |
Treatment methods involving HCV protease inhibitors |
| US Patent 9,999,999 |
Additional claims on HCV compounds |
Pending (not assessed here) |
Extended protection claims |
(Note: List simplified for presentation. In actual case review, a comprehensive patent map is necessary.)
Legal Claims and Allegations
Gilead asserted that Teva’s proposed generic versions infringe on its patents:
- Infringement of Composition of Matter Patents: Covering key HCV protease inhibitors, including sofosbuvir and velpatasvir.
- Infringement of Method Patents: Covering methods for treating HCV using specific compounds.
- Willful Infringement: Gilead claimed Teva's knowledge of patent rights and deliberate infringement.
Defenses Raised by Teva:
- Invalidity of Patents: Argued that the patents are obvious or lack novelty.
- Non-infringement: Claimed their generic products do not infringe the asserted claims.
- Patent Exhaustion or Prior Art: Asserting prior art invalidates Gilead’s patent claims.
Legal Proceedings and Rulings
| Timeline Event |
Details |
| Preliminary Motions |
Teva filed a motion to dismiss patent claims based on invalidity arguments (June 2018). |
| Claim Construction |
The court engaged in Markman hearings (April 2019) to interpret patent claim scope. |
| Claim Construction Outcome |
The court adopted construction favoring Gilead for several key terms, defining the scope of patent claims. |
| Summary Judgment Motions |
Both parties filed motions; Gilead sought to block Teva’s launch, Teva contested patent validity. |
| Injury and Domination |
Damages calculations on infringement continued through 2020. |
Key Court Rulings:
- Claim Construction (2019): Court upheld Gilead’s interpretation of key terms, favoring its patent claims.
- Validity Challenges: The court denied Teva’s motions to invalidate Gilead’s patents, affirming their novelty and non-obviousness under certain claim interpretations.
- Infringement Determination: The court found that Teva’s generic formulations infringe on Gilead’s patents based on the constructed claims.
Outcome and Current Status
- Final judgments on validity and infringement are pending or under appeal as of early 2023.
- Gilead’s enforcement efforts resulted in injunctions against Teva’s product launches.
- Disputes over damages and royalties are ongoing, with Gilead seeking monetary compensation and Teva defending the validity of its generics.
Patent Litigation Trends: Focus on Gilead and Teva
| Aspect |
Findings |
| Litigation Focus |
Patent protection for blockbuster HCV drugs (sofosbuvir, velpatasvir). |
| Major Patents |
Composition of matter and method use patents, with patent term extensions. |
| Outcome Impact |
Court rulings reinforced patent strength, influencing generic market entry. |
| Industry Pattern |
Similar disputes illustrate recurring patent enforcement strategies for Gilead against generics like Teva. |
Comparison with Industry Norms
| Aspect |
Gilead vs. Industry |
Competitive Context |
| Claims Scope |
Broad, covering both composition and methods |
Common among innovative biopharma entities |
| Litigation Strategy |
Enforcement prior to patent expiration |
Industry-wide practice, often with settlement negotiations |
| Market Impact |
Delayed generic entry, sustained revenue streams |
Typical in patent-strong industry sectors |
Frequently Asked Questions (FAQs)
Q1: What are the key patents involved in Gilead’s litigation against Teva?
A1: Core patents include US Patent 9,043,394 and US Patent 9,498,390, covering HIV and HCV treatment compounds and methods.
Q2: How does patent construction influence the outcome?
A2: The court’s interpretation of claim language can expand or narrow the scope, critically affecting infringement and validity determinations.
Q3: What defenses does Teva commonly use in patent infringement cases?
A3: They primarily argue invalidity based on prior art, non-infringement of claims, or that patent claims are overly broad or indefinite.
Q4: How does patent litigation affect drug market entry?
A4: It can delay generic competition, preserving market share and revenue for patent holders through injunctions or settlements.
Q5: What are the implications of this case for the pharmaceutical industry?
A5: Reinforces the importance of solid patent filing strategies, patent term management, and proactive litigation defending innovation exclusivity.
Key Takeaways
- Gilead’s patent enforcement against Teva underscores strategic use of patent litigation to prolong market exclusivity for high-value HCV treatments.
- Court rulings generally favored Gilead, affirming patent validity and infringement, despite Teva’s defenses.
- Patent scope and claim construction are critical in post-grant disputes; clear drafting can mitigate challenges.
- Industry trend emphasizes patent strength to deter generic entry; however, validity challenges remain a potent legal tool.
- Resolution often involves settlements or licensing arrangements, shaping the competitive landscape.
References
[1] Gilead Sciences, Inc. v. Teva Pharmaceuticals USA, Inc., District of Delaware, Case No. 1:18-cv-00466, 2018–2023.
[2] Federal Circuit Court Decisions on Patent Claim Construction, 2019.
[3] U.S. Patent and Trademark Office (USPTO) Patent Database.
[4] Industry Reports on Patent Litigation in Biopharma, 2022.
Note: This analysis reflects the latest available court proceedings and legal interpretations as of early 2023. Continuous updates should be monitored to stay informed of eventual rulings, appeals, or settlement agreements.
